Literature DB >> 9308945

Which prognostic factors influence the outcome of patients with surgically staged endometrial cancer treated with adjuvant radiation?

K M Greven1, B W Corn, D Case, P Purser, R M Lanciano.   

Abstract

PURPOSE: Despite the fact that retrospective reviews have documented pelvic failure rates ranging from 15-20% in patients with high-risk uterine-confined endometrial cancer who have received no or "inadequate" RT, the role of RT has been questioned. We sought to analyze pelvic control and disease-free survival for a large data base of women with corpus cancers managed with initial surgery followed by adjuvant irradiation. METHODS AND MATERIALS: Between 1983 and 1993, 294 patients received adjuvant postoperative RT from one of three academic radiation practices. RT consisted of vaginal brachytherapy alone in 28 patients, pelvic RT in 173 patients, pelvic RT with vaginal brachytherapy in 97 patients, and whole abdominal RT in 2 patients. Lymph nodes were evaluated in 49%. The median number of pelvic and periaortic LN in the pathology specimen were 6 and 4, respectively. Median follow up was 63 months.
RESULTS: 5-year disease-free survival (DFS) rate and pelvic control rates were 86 and 95%, respectively. Patient-related, treatment-related, and tumor-related characteristics were assessed for the effect on time to relapse. Unfavorable histology, older age, and capillary space invasion were univariately associated with decreased DFS and pelvic control. Pathologic Stage II patients had significantly worse DFS than Stage I patients. Multivariate analysis revealed that age, capillary space invasion, and histology were jointly predictive of disease free survival.
CONCLUSION: The excellent pelvic control and disease-free survival of patients with uterine-confined disease in this series suggest that adjuvant RT should continue for patients with high risk disease. This analysis of a large group of postoperatively treated patients will provide a basis for determining alternative treatment strategies for patients who have an increased risk of disease recurrence despite RT.

Entities:  

Mesh:

Year:  1997        PMID: 9308945     DOI: 10.1016/s0360-3016(97)00323-4

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  5 in total

1.  The effect of lymphadenectomy and radiotherapy on recurrence and survival in endometrial carcinoma. Experience in a population reference centre.

Authors:  Meritxell Arenas; Marina Gascón; Àngels Rovirosa; Víctor Hernández; Francesc Riu; Iolanda López; Angel Montero; Sebastià Sabater
Journal:  Rep Pract Oncol Radiother       Date:  2014-10-14

2.  Incidence of radiation toxicity in cervical cancer and endometrial cancer patients treated with radiotherapy alone versus adjuvant radiotherapy.

Authors:  Andrzej Roszak; Zaneta Wareńczak-Florczak; Krystyna Bratos; Piotr Milecki
Journal:  Rep Pract Oncol Radiother       Date:  2012-09-05

3.  High-risk surgical stage 1 endometrial cancer: analysis of treatment outcome.

Authors:  Gustavo A Viani; Barbara F Patia; Antonio C Pellizzon; Marcel D De Melo; Paulo E Novaes; Ricardo C Fogaroli; Maria A Conte; Joao V Salvajoli
Journal:  Radiat Oncol       Date:  2006-08-03       Impact factor: 3.481

4.  Postoperative Radiotherapy Alone Versus Chemoradiotherapy in Stage I-II Endometrial Carcinoma: An Investigational and Propensity Score Matching Analysis.

Authors:  Jong Hoon Lee; Hyo Chun Lee; Sung Hwan Kim; Mi Joo Chung; Song Mi Jeong; Sung Jong Lee; Joo Hee Yoon; Dong Choon Park
Journal:  Cancer Res Treat       Date:  2014-09-15       Impact factor: 4.679

5.  Dosimetry and toxicity outcomes in postoperative high-dose-rate intracavitary brachytherapy for endometrial carcinoma.

Authors:  Eric D Donnelly; Sunpreet Rakhra; Irene Helenowski; Mahesh Gopalkrishnan; John Lurain; Julian Schink; Diljeet Singh; Jonathan Strauss; William Small
Journal:  J Contemp Brachytherapy       Date:  2012-09-29
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.